Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety evaluation of Sodium-glucose cotransporter 2 inhibitors for cancer risk in specific populations: systematic review and meta-analysis.

Frontiers in clinical diabetes and healthcare·2026
Same author

Comparative efficacy of mind-body exercises for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis.

Clinical rehabilitation·2026
Same author

Inhibiting RhoA Activation Via GDP-State Stabilization to Relieve Heart Failure.

Circulation research·2026
Same author

A miniaturized mouse extracorporeal circulation model to characterize early hematologic and metabolic alterations.

Frontiers in physiology·2026
Same author

The role and mechanism of histone deacetylase in COPD.

Molecular and cellular biochemistry·2026
Same author

Deletion of RhoGDI Protects Against Hepatic Steatosis via Improved Mitochondrial Metabolism in Mice.

International journal of molecular sciences·2026

Related Experiment Video

Updated: May 29, 2026

Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

Phosphodiesterases inhibition by Bacilli Calmette-Guérin contributes to decrease asthma in allergic rats.

Yajuan Wang1, Yali Jiang, Huifang Tang

  • 1Zhejiang Respiratory Drugs Research Laboratory of State Food and Drug Administration of China, College of Medicine, Zhejiang University, Hangzhou 310058, China.

Iranian Journal of Allergy, Asthma, and Immunology
|September 6, 2011
PubMed
Summary
This summary is machine-generated.

Bacilli Calmette-Guérin (BCG) treatment reduced asthma symptoms in rats by decreasing phosphodiesterases (PDEs) and increasing cAMP levels. This suggests BCG may prevent allergic airway inflammation and hyperresponsiveness.

More Related Videos

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
08:58

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Published on: July 10, 2018

Acupuncture in a Rat Model of Asthma
07:14

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

Related Experiment Videos

Last Updated: May 29, 2026

Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
08:58

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Published on: July 10, 2018

Acupuncture in a Rat Model of Asthma
07:14

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

Area of Science:

  • Immunology
  • Pharmacology
  • Respiratory Medicine

Background:

  • Decreased cyclic adenosine monophosphate (cAMP) levels are implicated in asthma pathogenesis.
  • Phosphodiesterases (PDEs) hydrolyze cAMP, and their levels are elevated in allergic asthma.
  • Bacilli Calmette-Guérin (BCG) has shown potential in modulating immune responses, but its effect on asthma via PDE regulation is unclear.

Purpose of the Study:

  • To investigate the effect of BCG on allergen-induced asthma in a rat model.
  • To determine if BCG's protective effects are mediated by modulation of phosphodiesterases (PDEs) and cyclic adenosine monophosphate (cAMP) levels.

Main Methods:

  • Ovalbumin/pertussis sensitization and challenge in Sprague-Dawley rats.
  • Assessment of lung inflammation and airway hyperresponsiveness (AHR).
  • Measurement of lung cAMP levels, adenylate cyclase activity, PDE activity (HPLC), and PDE mRNA expression (RT-PCR).

Main Results:

  • BCG administration significantly attenuated allergen-induced lung inflammation and airway hyperresponsiveness.
  • BCG treatment led to increased cAMP levels in the lungs of allergic rats.
  • BCG decreased the activity and mRNA expression of specific PDEs (PDE4A, 4C, 5, 8) in the lungs.

Conclusions:

  • BCG effectively mitigates airway inflammation and hyperresponsiveness in a rat asthma model.
  • BCG's beneficial effects are associated with reduced PDE activity and expression, alongside increased cAMP levels.
  • BCG may offer a therapeutic strategy for asthma by modulating PDE activity and cAMP homeostasis.